Compare AbbVie Inc (ABBV) vs Plby Group Inc (PLBY) Price & Performance

AbbVie IncTrade

Plby Group IncTrade

Price performance (Past 24H)

Key statistics

AbbVie Inc vs Plby Group Inc — how do they compare? AbbVie Inc trades at $248.34 (market cap $441.94B), while Plby Group Inc trades at $1.26 (market cap $162.94M). The key difference: AbbVie Inc is far larger — about 2712.3× Plby Group Inc's market cap, and AbbVie Inc pays a 2.77% dividend while Plby Group Inc pays none. Which is the better fit depends on your goals.

	ABBV	PLBY
Market Cap	$441.94B	$162.94M
Sector	Health	Consumer Cyclical
52-Week High	$263.58	$2.71
52-Week Low	$197.38	$1.11
Enterprise Value	$506.19B	$308.52M
Dividend Yield	2.77%	—

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AbbVie Inc

AbbVie (ABBV) trades at $249.9, up 0.8% on the day, with strong analyst support (29 Buy, 1 Sell) and a $278.69 consensus price target. Recent quarterly earnings have consistently beaten estimates, driven by robust immunology drug sales. The stock shows a bullish technical trend, supported by moving averages, and the company maintains solid cash flow and dividend payments.

Outlook is positive with revenue growth and pipeline advancements, though high P/E and debt levels pose risks. The stock offers a compelling buy case for growth and income investors, balanced by execution and patent expiry challenges ahead.

Plby Group Inc

PLBY trades at $1.28, up 8.47% in the last session, with a bullish technical signal from moving averages. The company shows improving fundamentals, with Q2 2026 revenue growth and a return to operating profitability, while net income margin remains slim at 0.23%. Recent news highlights inclusion in the Russell 2000 index and a share repurchase program.

The outlook is cautiously optimistic, supported by analyst consensus and positive cash flow trends, but high debt levels and inconsistent earnings history pose risks. Investment opportunity lies in brand licensing growth, while execution and competitive pressures are key watchpoints.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

ABBV

J&J and AbbVie report strong quarters with contrasting dividend and growth strategies.24/7 Wall Street · 4 hours agoBullish HDV's top dividend payers—Exxon, Chevron, J&J, AbbVie—are mostly safe, supporting steady income.24/7 Wall Street · 6 hours agoBullish Fidelity Dividend ETF's payout is safe but not ideal for steady income due to variable quarterly dividends.24/7 Wall Street · 1 day agoNeutral View details →

PLBY

Playboy reports strong Q2 earnings, stock jumps on stable licensing and Honey Birdette's turnaround.Seeking Alpha · 9 hours agoBullish View details →

About AbbVie Inc

AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.

About Plby Group Inc

PLBY Group Inc is a pleasure and leisure company. The company's segment includes Licensing, Direct-to-Consumer, and Digital Subscriptions and Content. It generates maximum revenue from the Direct-to-Consumer segment. Direct-to-Consumer operations include consumer products sold through third-party retailers or online direct-to-customer. Geographically, it derives a majority of revenue from the United States.